Screening criteria for enrolling patients will include RECIST tumor staging criteria, screening patients with tumor diameters and relative increases of 0%–20% after previous EGFR‐TKI monotherapy, and increased CEA levels after previous EGFR‐TKI monotherapy.8 This evidence concerns the gene CEACAM5 and neoplasm.